The Arcturus variant of COVID-19, also known as the XBB.1.16 strain, has been spreading rapidly worldwide and detected in 34 countries. This new variant is believed to be 1.2 times more infectious than previous subvariants and has been prevalent in India and all four nations of the United Kingdom.
Arcturus was first discovered in January and was assigned as a "variant of interest" by the World Health Organization in mid-April due to its unique traits, including a mutant spike protein that increases its contingency.
Despite its increased infectivity, no evidence suggests that Arcturus causes more severe illness or has reduced vaccination effectiveness. However, individuals infected with this variant may experience conjunctivitis, characterized by redness and eye inflammation, along with other common COVID-19 symptoms such as cough, fever, fatigue, diarrhea, sore throat, shortness of breath, and headache. Conjunctivitis typically resolves on its own but may sometimes require antiviral medication.
Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.
Please login to comment on this article